Supplementary Appendix - Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Published: 08-08-2019| Version 1 | DOI: 10.17632/cm27w42ff3.1
Contributor:
Amy Paller

Description

Supplementary Appendix for the publication of Paller A. et al. Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study. J Am Acad Dermatol 2019

Files